AB Science SA (DE:A8D)
FRANKFURT:A8D
A8D Stock Chart & Stats
€1.50
€0.32(25.88%)
At close: 4:00 PM EST
€1.50
€0.32(25.88%)
Day’s Range― - ―
52-Week Range€0.90 - €1.69
Previous CloseN/A
Volume1.50K
Average Volume (3M)219.00
Market Cap
€61.40M
Enterprise Value€61.32M
Total Cash (Recent Filing)€10.18M
Total Debt (Recent Filing)€4.24M
Price to Earnings (P/E)―
Beta0.11
Next Earnings
Sep 25, 2026EPS Estimate
-0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding69,776,230
10 Day Avg. Volume360
30 Day Avg. Volume219
Financial Highlights & Ratios
PEG Ratio0.73
Price to Book (P/B)-5.48
Price to Sales (P/S)80.33
P/FCF Ratio-20.63
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.14
Revenue Forecast (FY)€1.20M
Bulls Say, Bears Say
Bulls Say
Improving Revenue TrendSustained revenue growth into 2025 indicates product or program traction and supports longer-term commercial optionality. A growing top line, even from a small base, reduces binary development risk by validating demand and improving prospects for scaling clinical/commercial efforts over months.
Material Debt ReductionSignificant debt reduction materially eases solvency pressure and lowers near-term refinancing risk. With much smaller nominal debt, fixed financing costs decline and management has more optionality to allocate cash toward trials or milestones rather than servicing legacy liabilities.
Focused, Diversified PipelineA clear focus on a platform small‑molecule (masitinib) tested across multiple indications gives multiple commercialization pathways. That therapeutic breadth increases the probability one program reaches approval and creates repeatable R&D learning and potential cross-indication value over the medium term.
Bears Say
Persistently Negative EquityChronic negative shareholder equity is a structural solvency red flag that constrains financing options and strategic flexibility. It signals accumulated losses that can limit lender and partner appetite and increases the likelihood of dilutive capital raises to sustain operations over coming quarters.
Renewed Cash BurnReturn to significant negative operating and free cash flow creates an ongoing funding requirement. For a development-stage biotech, sustained cash burn raises execution risk: delays or additional capital raises could dilute shareholders or slow programs, affecting multi‑quarter development timelines.
Deep Unprofitability Vs Small Revenue BaseLarge, persistent losses compared with a small revenue base mean the company lacks internal cash generation to fund growth. This structural mismatch increases dependence on external financing and creates execution and survival risk if capital markets tighten or milestones slip.
AB Science SA News
A8D FAQ
What was AB Science SA’s price range in the past 12 months?
AB Science SA lowest stock price was €0.90 and its highest was €1.69 in the past 12 months.
What is AB Science SA’s market cap?
AB Science SA’s market cap is €61.40M.
When is AB Science SA’s upcoming earnings report date?
AB Science SA’s upcoming earnings report date is Sep 25, 2026 which is in 108 days.
How were AB Science SA’s earnings last quarter?
AB Science SA released its earnings results on May 13, 2026. The company reported -€0.07 earnings per share for the quarter, the consensus estimate of -€0.07 by €0.
Is AB Science SA overvalued?
According to Wall Street analysts AB Science SA’s price is currently Overvalued.
Does AB Science SA pay dividends?
AB Science SA does not currently pay dividends.
What is AB Science SA’s EPS estimate?
AB Science SA’s EPS estimate is -0.07.
How many shares outstanding does AB Science SA have?
AB Science SA has 69,776,230 shares outstanding.
What happened to AB Science SA’s price movement after its last earnings report?
AB Science SA reported an EPS of -€0.07 in its last earnings report, expectations of -€0.07. Following the earnings report the stock price went down -1.333%.
Which hedge fund is a major shareholder of AB Science SA?
Currently, no hedge funds are holding shares in DE:A8D
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
AB Science SA
AB Science S.A. is a pharmaceutical company dedicated to the discovery, development, and commercialization of protein kinase inhibitors for applications in both human and animal health. Its primary drug candidate, masitinib, a tyrosine kinase inhibitor, is currently undergoing late-stage (Phase III) clinical investigations for a range of serious conditions including prostate cancer, pancreatic cancer, amyotrophic lateral sclerosis (ALS), multiple sclerosis, Alzheimer's disease, severe asthma, and mastocytosis. Additionally, masitinib is being evaluated in Phase II clinical trials for the treatment of Covid-19. The company's pipeline also features AB8939, a synthetic microtubule destabilizer aimed at treating acute myeloid leukemia, and AB20001, which is in Phase 2 trials to assess the safety and efficacy of masitinib combined with isoquercetin in hospitalized patients experiencing moderate to severe COVID-19. Masitinib is sold under the brand name Masivet in the European market. AB Science S.A. was founded in 2001 and is based in Paris, France.